Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicenter Stop Imatinib in Japan adult leukemia study group study
Phase 2
- Conditions
- Chronic Myeloid Leukemia Chronic phase
- Registration Number
- JPRN-UMIN000011971
- Lead Sponsor
- Japan Adult Leukemia Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 62
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients with a history of treatment by the other TKI. 2)Patients with a history of hematopoietic stem cell transplantation. 3)Patients who have had blast crisis or accelerated CML. 4) Patients who have lost CMR during imatinib treatment. 5)Patients who have discontined imatinib treatment because of poor adherence. 6)Patients who do not want to re start imatinib after lost of MMR. 7)Other patients whom the investigator considers to be unsuitable for participation in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method MMR rate at 12 M after discontinuation of treatment
- Secondary Outcome Measures
Name Time Method